Neurogenetic Testing Market Report 2026

Neurogenetic Testing Market Overview

• Neurogenetic Testing market size has reached to $0.7 billion in 2025 • Expected to grow to $1.24 billion in 2030 at a compound annual growth rate (CAGR) of 11.9% • Growth Driver: Rising Prevalence Of Neurological Disorders Fuels Demand For Neurogenetic Testing • Market Trend: Innovative Products Driving Growth In The Neurogenetic Testing Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurogenetic Testing Market?

Neurogenetic testing is a type of genetic testing that focuses on identifying genetic variations associated with neurological disorders or conditions affecting the nervous system. It is used for diagnosing, predicting, and managing neurological disorders, as well as facilitating research and the development of personalized treatment approaches in the field of neurology and genetics. The main types of neurogenetic testing market are microarray analysis, whole-exome sequencing (WES), multiplex ligation dependent probe amplification (MLPA), polymerase chain reaction (PCR) tests, and other types. Microarray analysis is a technique used in neurogenetic testing to simultaneously analyze the expression levels of thousands of genes. The various diseases are rare genetic disorder, cancer, cystic fibrosis, sickle cell anemia, duchenne muscular dystrophy, thalassemia, huntington’s disease, fragile x syndrome, and other diseases involved by various end-users such as hospitals, specialty clinics, research institutes, and diagnostics laboratories.

What Is The Neurogenetic Testing Market Growth Forecast?

The neurogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $1.24 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to growing demand for next-generation sequencing, increasing expansion of clinical exome sequencing, rising investment in genetic research, development of advanced molecular diagnostic tools, growing adoption of personalized neurological treatment approaches. Major trends in the forecast period include rising adoption of whole-exome sequencing technologies, increasing use of pcr-based neurological genetic tests, growing implementation of microarray analysis, expansion of testing for rare neurological genetic disorders, growing demand for early diagnosis and predictive testing.

Global Neurogenetic Testing Market Segmentation

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types 2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases 3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories Subsegments: 1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray 2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing 3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection 4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR) 5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What Are The Drivers Of The Neurogenetic Testing Market?

The rising prevalence of neurological disorders is expected to propel the growth of the neurogenetic testing market. Neurological disorders refer to any conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. The prevalence of neurological disorders are the cause of genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Neurogenetic testing significantly enhances the diagnosis, treatment, and management of neurological disorders by offering personalized insights into genetic risk factors, guiding treatment decisions, and empowering individuals and families to make informed healthcare choices, thereby improving patient care and outcomes. For instance, in October 2023, according to the World Federation of Neurology, a UK-based charity, reflecting an accelerating global health burden, neurological disorders now represent the second-leading cause of death and the primary cause of disability worldwide, with more than 40 percent of the global population affected in 2023 and the number of individuals living with brain disease projected to nearly double by 2050. Therefore, the rising prevalence of neurological disorders is expected to drive the growth of the neurogenetic testing industry. The rising prevalence of cancer is expected to propel the growth of the neurogenetic testing market. Cancer refers to a disease in which abnormal cells divide uncontrollably and destroy body tissue. Cancer cases are increasing due to several factors, including the obesity epidemic, inherited genetic abnormalities, hepatitis B and C viruses, Epstein-Barr virus (EBV), and human papillomavirus (HPV). Neurogenetic testing is essential to the management of cancer, as it assists in choosing the most effective course of treatment, evaluates prognoses, identifies high-risk patients, and provides individualized care based on the particular genetic profile and family history of each patient. For instance, in January 2024, according to the data published by the American Cancer Society, a US-based non-profit organization, the United States is projected to see 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, compared to 1,958,310 cases and 609,820 deaths in 2023. Therefore, the rising prevalence of cancer is driving the growth of the neurogenetic testing industry.

Key Players In The Global Neurogenetic Testing Market

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Global Neurogenetic Testing Market Trends and Insights

Major companies operating in the neurogenetic testing market are developing innovative products, such as whole-genome sequencing, to enhance the accuracy and scope of genetic analysis, enabling more comprehensive and personalized testing for neurological disorders. Whole-genome sequencing (WGS) is a comprehensive genetic testing method that involves determining the complete DNA sequence of an individual's entire genome. For instance, in March 2024, Nucleus Genomics, a US-based company that provides genetic analysis, launched a DNA analysis product. Through this platform empower people with a deeper understanding of their genetic predispositions, facilitating informed decisions about their health and well-being. With cutting-edge technology and expert genetic counseling services, Nucleus Genomics is set to redefine the landscape of genetic testing, bringing the power of whole-genome sequencing directly into the hands of individuals and revolutionizing the field of genomic medicine.

Regional Outlook

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurogenetic Testing Market?

The neurogenetic testing market includes revenues earned by entities by providing services such as diagnostic testing, predictive testing, carrier screening, and prenatal testing and related products such as genetic testing kits, DNA sequencing platforms, and bioinformatics software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurogenetic Testing Market Report 2026?

The neurogenetic testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurogenetic testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.